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Purpose/Objective: We conducted a retrospective analysis of 
stage IVA uterine cervical cancer patients from several 
clinical trials of carbon ion radiotherapy (C-ion RT) in 
National Institute of Radiological Sciences. The purpose of 
this study was evaluation of the toxicity and efficacy of C-ion 
RT for FIGO stage IVA uterine cervical cancer. 
Materials and Methods: Between June 1995 and January 
2014, we have conducted 8 clinical trials of C-ion RT for 
locally advanced squamous cell carcinoma or adenocarcinoma 
of the cervix, and 29 patients with FIGO stage IVA uterine 
cervical cancer were identified in 7 clinical trials. Mean age 
was 56 years old (range 31-79 years old). Median tumor size 
was 6.7 cm (range 3.5-11 cm). Patients with rectal invasion 
were excluded from this analysis because these cases were 
ineligible in our clinical trial. Nineteen of 29 patients had 
enlarged lymph nodes in pelvis. Histologically, 20 patients 
had squamous cell carcinoma and 9 had adenocarcinoma. C-
ion RT was performed as a dose-escalation study at the 
beginning, total dose to cervical tumor was 52.8-74.4 gray 
equivalents, and concurrent chemotherapy was combined in 
4 patients. 
Results: The median follow up time was 28.1 months (range 
4.2-213.8 months). The numbers of Grade 2 or higher major 
late complications were 2 patients (6.9%) in the bladder, and 
6 patients (20.7%) in the rectosigmoid colon. Vesicovaginal 
fistula was observed in 6 patients after the treatment. The 3 
years overall survival rates (3yOS) was 46.7%, the 3 years 
local control rates (3yLC) was 64.9%, and the 3 years 
progression free survival rates (3yPFS) was 33.6%. The 3yOS, 
3yOS, and 3yPFS of patients with squamous cell carcinoma 
were 44.9%, 62.2%, and 34.9%, respectively. Those with 
adenocarcinoma were 52.5%, 75.0%, and 23.9%, respectively. 
Conclusions: Although the number of patients in this analysis 
was small, these result suggested that C-ion RT for FIGO 
stage IVA uterine cervical cancer would be an effective 
method.  
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Purpose/Objective: To determine the recommended 
preoperative dose of large-field IMRT chemoradiation along 
with simultaneous integrated boost (SIB) dose escalation on 
the tumor and pelvic nodes in locally advanced cervical 
carcinoma (LACC). 
Materials and Methods: A radiation dose of 40 Gy over four 
weeks, 2 Gy per fraction, was delivered to the tumor and the 
lymphatic drainage (planning target volume, PTV3), which 
encompassed a volume larger than standard (upper field 
border: L3 vertebra), concurrently with chemotherapy 
(cisplatin and 5-fluorouracil). Radiation dose was escalated 
to the pelvic nodes (PTV2) and macroscopic disease (PTV1) 
with a SIB strategy. Three dose levels were planned as shown 
in Table 1 up to a dose of 50/2.5 Gy on PTV1. Patients were 
treated in cohorts of three to six per group using a phase I 
study design. The recommended dose was exceeded if 2 of 6 
patients in a cohort experienced dose-limiting toxicity (DLT). 
 
Results: 19 patients (median age: 46 years; FIGO stage IB2: 
3, IIB: 10, IIIA: 4, IIIB: 2) were enrolled. Median follow-up was 
36 months (9–60 months). The predominant DLTs were 
gastrointestinal . Since two DLTs (grade 3 diarrhoea, n=2), 
were observed in 6 patients at level III, the decision was to 
close the trial and to consider level II as the recommended 
phase II dose. In the post-operative period, 2 (10.5%) patients 
showed grade 3 GU complications. Concerning long term 
toxicity, actuarial 2y GU toxicity (≥ grade 2) free survival was 
83.6%, neither severe GI complications (≥2) nor late skin 
toxicity (≥2) were observed. Planning constraints for normal 
tissues were always respected except in the case of small 
bowel where only 2 patients respected V15<120 cc 
constraint; in the majority of LACC it was largely exceeded 
with a median value of 268.9 cc (range 96-481 cc). Three of 
the four patients with severe GI toxicity did not meet the 
QUANTEC small bowel constraint V15<120 cc. Concerning 
pathologic response 12 (63.1%) complete response or 
microscopic residual disease were recorded. The 2-year local 
control was 89.5% (median LC: not reached), while the 2-year 
disease free survival (DFS) was 82.0% (median DFS: not 
reached). Death of disease was recorded in 2 of 18 patients 
(10.5%) and the 2-year overall survival (OS) was 88.8% 
(median OS: not reached).  
Conclusions: In a series of 19 LACC patients treated by SIB-
IMRT chemoradiation followed by radical surgery, 40 Gy on 
lumboaortic nodes and 45 Gy on pelvic nodes and 
macroscopic disease were the recommended doses. 
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Purpose/Objective: To evaluate the impact of adjuvant 
taxane-platinum-based chemoradiation with preventive para-
aortic zone irradiation to outcome improvement in 
endometrial cancer II-III FIGO patients.  
Materials and Methods: From January 2008 to April 2014 
database of 250 EC patients’ medical histories and outpatient 
cards was analyzed retrospectively; all cases were re-staged 
according to 2009 FIGO classification  
115 patients with endometrial cancer II-III stage were 
considered eligible and were included in the study in two 
arms. 49(43%) pts. were enrolled in research group A. All of 
them undergone total hysterectomy , with pelvic 
lymphadenectomy in 18(36,7%), pelvic-paraaortic 
lymphadenectomy - in 8(16%) of them, followed by adjuvant 
chemoradiation. Image-guided external beam radiotherapy 
combined with brachy had been performed in 100% , 33(61%) 
patients were supplemented with para-aortic lymph node 
irradiation to the level of Th12-L2. All patients then received 
2-6 courses of taxane-platinum adjuvant chemotherapy. Total 
mean dose to pelvic (obturator, internal/ external/ common 
iliac) and para-aortic lymphnodes TD44Gy (30-50Gy) was 
achieved, with increase to 60Gy (36-74) in the vaginal vault 
because of Ir-192 HDR brachytherapy. 
66 (57%) patients were enrolled in control arm B; all of them 
undergone total hysterectomy, with pelvic lymphadenectomy 
in 14 (21%) and pelvic-paraaortic lymphadenectomy in 7 (10, 
6%) of them, followed by conventional external beam 
radiotherapy on the pelvic region TD 40-44Gy, added by Co-
60 HDR brachytherapy to vaginal cuff.  
Results: The median follow-up was 12 months (range, 1-79 
months). We registered the significant improvement in 
overall and disease-free survival in arm A, with 11% decrease 
of loco-regional relapse rate (from 20% to 9% in stage II pts., 
from 36% to 21% in stage III pts.) and 11% decrease (from 22% 
to 11%) of distant metastasis rate in stage III pts. Treatment 
was tolerable: no significant difference in adverse effect 
rates and grade was registered in arm A inspite of irradiation 
field extention, mainly because of specific therapeutic 
prevention.  
Conclusions: Adjuvant taxane-platinum-based 
chemoradiation with preventive para-aortic zone irradiation 
improves one year overall survival, disease-free and cancer-
specific survival for patients with II-III FIGO with acceptable 
side effects rate. 
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Purpose/Objective: This is a retrospective study, to evaluate 
the effect of treatment breaks due to anemia and blood 
transfusions on treatment response in cervical cancer 
patients who completed the standard treatment.  
Materials and Methods: Medical records of 151 patients, 
from Nov. 1st 2012 to Oct.31st 2013, were reviewed for 
demographic variables, stage of the disease, total dose 
delivered, degree of anemia, episodes of blood transfusions, 
treatment breaks and treatment duration. RECIST criteria for 
treatment response, FIGO for cervical cancer staging and 
RTOG for degree of anemia were used. The standard cervical 
cancer treatment used was concurrent chemo- radiotherapy 
followed by LDR intracavitary brachy therapy. The CHI square 
testing and 95 % significance level was applied. 
Results: A total of 151 cervical cancer patients were booked 
over the study period, Of which:- Stage IA & IB2 10%, IIA-IIB 
29%, IIIA- IIIB 48.4%, and IV 16.6%. Of the total, 41 patients 
did not start treatment in spite of booking. The rest 110 
(72.6%) started treatment with curative and palliative intent, 
Out of which,64 patients completed curative treatment 
course, of which 90.4% had good response and 9.6% didn't 
respond and/or disease progressed on treatment. There were 
40 episodes of blood transfusions, the 42.5% given before 
commencement of treatment and 57.5% during the course. 
Most of the treatment breaks were due to consequences of 
anemia and mainly for blood transfusions. The mean 
treatment break was 2.93 days. Those who presented with < 
10 HB, needed more transfusions during the course (p< 0.01). 
Response rate of those with HB >_ 10 gm at presentation was 
not significantly better than those with HB < 10 gm and 
needed transfusions in the course and short treatment breaks 
( p > 0.05).  
Conclusions: Cervical cancer patients who presented low HB 
at presentation, in spite of HB buildup transfusions at the 
beginning of the treatment are likely to need more 
transfusions during the course and their treatment response 
is not significantly different from those who started 
treatment with normal HB. High number of advanced cases 
and drop outs calls for an extensive study of KAP toward 
cancer and its treatment in the study society. 
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Purpose/Objective: Rectal dose defined as a point dose in 
ICRU 38 is not a good surrogate for actual dose delivered. 
Image based brachytherapy using CT or MRI allows for 
volumetric assessment of radiation dose. The possibility of 
developing rectal complications is best quantified from 
measuring dose to 2cc (D2cc) of rectum. In this study we 
investigated the effect of rectal distension on rectal dose 
parameters in patients of locally advanced cervical cancers 
undergoing CT based high dose rate brachytherapy and 
generated a model to predict the increase in D2cc with 
increasing rectal distension. 
Materials and Methods: Between January and October 2013, 
'planning CT scans' of 30 locally advanced cervical cancer 
patients undergoing three dimensional brachytherapy were 
reviewed retrospectively. Rectum was contoured from 
rectosigmoid junction superiorly until the ischial tuberosity 
inferiorly. The maximum rectal distension (MRD) was 
measured as the largest anterior-posterior diameter of the 
rectum opposite to the line joining the central tandem tip 
